Publications
527 results found
Kronenberg F, Mora S, Stroes ESG, et al., 2022, Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, EUROPEAN HEART JOURNAL, Vol: 43, Pages: 3925-3946, ISSN: 0195-668X
- Author Web Link
- Cite
- Citations: 4
Ray KK, Catapano AL, Diamand F, et al., 2022, Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients, Publisher: OXFORD UNIV PRESS, Pages: 2377-2377, ISSN: 0195-668X
Catapano AL, Manu MC, Burden A, et al., 2022, LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study, Publisher: OXFORD UNIV PRESS, Pages: 2373-2373, ISSN: 0195-668X
Ray KK, Perrone-Filardi P, Ebenbichler C, et al., 2022, Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry, Publisher: OXFORD UNIV PRESS, Pages: 2667-2667, ISSN: 0195-668X
Ray KK, Manu MC, Burden A, et al., 2022, Cardiovascular risk factors in patients with and without a history of atherosclerotic cardiovascular disease in the SANTORINI study and estimation of risk, Publisher: OXFORD UNIV PRESS, Pages: 2255-2255, ISSN: 0195-668X
Ray KK, Perrone-Filardi P, Ebenbichler C, et al., 2022, High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry, Publisher: OXFORD UNIV PRESS, Pages: 2666-2666, ISSN: 0195-668X
Stevens C, Mahani A, Ray K, et al., 2022, Use of ensemble machine learning in screening electronic health records: a scoping review, RSS International Conference 2022
Toth PP, Schwartz GG, Nicholls SJ, et al., 2022, Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease, AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, Vol: 11, ISSN: 2666-6677
- Author Web Link
- Cite
- Citations: 2
Ballantyne CM, Bays HE, Louie MJ, et al., 2022, Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid, JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol: 11
Vallejo-Vaz A, Stevens C, Dharmayat K, et al., 2022, Identification, characteristics and management of adults with heterozygous Familial Hypercholesterolaemia in high and non-high income countries participating in the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC), European Atherosclerosis Society Congress 2022, Publisher: Elsevier, Pages: 15-16, ISSN: 0021-9150
Gunn LH, McKay AJ, Feng A, et al., 2022, Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease, ATHEROSCLEROSIS PLUS, Vol: 49, Pages: 20-27
Ray KK, Haq I, Bilitou A, et al., 2022, BASELINE CHARACTERISTICS AND MANAGEMENT OF HIGH- AND VERY HIGH-RISK PATIENTS WITH HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA IN THE MULTINATIONAL OBSERVATIONAL SANTORINI STUDY, Publisher: ELSEVIER IRELAND LTD, Pages: E47-E47, ISSN: 0021-9150
Ray KK, Haq I, Bilitou A, et al., 2022, Cardiovascular risk assessment by physicians and lipid-lowering therapy prescribing in high- and very high-risk patients: Results from the multinational observational santorini study, Atherosclerosis, Vol: 355, Pages: 249-249, ISSN: 0021-9150
Ray KK, Haq I, Bilitou A, et al., 2022, CARDIOVASCULAR RISK ASSESSMENT BY PHYSICIANS AND LIPID-LOWERING THERAPY PRESCRIBING IN HIGH- AND VERY HIGH-RISK PATIENTS: RESULTS FROM THE MULTINATIONAL OBSERVATIONAL SANTORINI STUDY, Publisher: ELSEVIER IRELAND LTD, Pages: E331-E331, ISSN: 0021-9150
Ray KK, Nicholls S, Ditmarsch M, et al., 2022, OBICETRAPIB LOWERS LDL-C IN PATIENTS ON HIGH INTENSITY STATINS: RESULTS FROM THE ROSE TRIAL (NCT04753606), Publisher: ELSEVIER IRELAND LTD, Pages: E11-E12, ISSN: 0021-9150
Ray KK, Bruckert E, Perrone-Filardi P, et al., 2022, FINAL RESULTS FROM THE PAN-EUROPEAN OBSERVATIONAL HEYMANS STUDY SUGGEST A MISMATCH BETWEEN GUIDELINES AND PCSK9I REIMBURSEMENT CRITERIA, Publisher: ELSEVIER IRELAND LTD, Pages: E46-E47, ISSN: 0021-9150
Vallejo-Vaz AJ, Dharmayat KI, Nzeakor N, et al., 2022, RESIDUAL RISK OF MAJOR ADVERSE CARDIOVASCULAR AND LIMB EVENTS AMONG DIFFERENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PHENOTYPES RECEIVING GUIDELINE-RECOMMENDED ANTIPLATELET MONOTHERAPY: THE RESRISK STUDY, Publisher: ELSEVIER IRELAND LTD, Pages: E62-E63, ISSN: 0021-9150
Dharmayat KI, Vallejo-Vaz AJ, Stevens CA, et al., 2022, Global perspective of paediatric Familial Hypercholesterolaemia: Analysis from the EAS FHSC registry on over 11,200 children and adolescents with heterozygous Familial Hypercholesterolaemia from 44 countries, 90th European Atherosclerosis Society (EAS) Congress, Publisher: Elsevier, Pages: E13-E13, ISSN: 0021-9150
Brandts J, Bray S, Villa G, et al., 2022, LDL-CHOLESTEROL GOAL ATTAINMENT THROUGH OPTIMAL IMPLEMENTATION OF THE 2019 ESC/EAS DYSLIPIDEMIA TREATMENT ALGORITHM IN EUROPEAN PATIENTS WITH/WITHOUT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: SIMULATION STUDY FROM DA VINCI, Annual Meeting of the European-Astronomical-Society (EAS), Publisher: ELSEVIER IRELAND LTD, Pages: E54-E54, ISSN: 0021-9150
- Author Web Link
- Cite
- Citations: 1
McKay AJ, Gunn LH, Ray KK, 2022, Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort, ATHEROSCLEROSIS, Vol: 354, Pages: 68-74, ISSN: 0021-9150
- Author Web Link
- Cite
- Citations: 2
Masson W, Corral P, Barbagelata L, et al., 2022, Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review, JOURNAL OF CLINICAL LIPIDOLOGY, Vol: 16, Pages: 562-573, ISSN: 1933-2874
- Author Web Link
- Cite
- Citations: 1
Ballantyne CM, Banach M, Bays HE, et al., 2022, Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study), AMERICAN JOURNAL OF CARDIOLOGY, Vol: 174, Pages: 1-11, ISSN: 0002-9149
- Author Web Link
- Cite
- Citations: 19
Ray K, Kallend D, Landmesser U, et al., 2022, †Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled Post hoc Analysis of the phase 3 ORION-9, ORION-10, and ORION-11 Randomized Controlled Trials, Journal of Clinical Lipidology, Vol: 16, Pages: e63-e63, ISSN: 1933-2874
Navarese EP, Grzelakowska K, Mangini F, et al., 2022, The spoils of war and the long-term spoiling of health conditions of entire nations, ATHEROSCLEROSIS, Vol: 352, Pages: 76-79, ISSN: 0021-9150
- Author Web Link
- Cite
- Citations: 1
Komodromos M, Aboagye EO, Evangelou M, et al., 2022, Variational Bayes for high-dimensional proportional hazards models with applications within gene expression, BIOINFORMATICS, Vol: 38, Pages: 3918-3926, ISSN: 1367-4803
Motivation:Few Bayesian methods for analyzing high-dimensional sparse survival data provide scalable variable selection, effect estimation and uncertainty quantification. Such methods often either sacrifice uncertainty quantification by computing maximum a posteriori estimates, or quantify the uncertainty at high (unscalable) computational expense.Results:We bridge this gap and develop an interpretable and scalable Bayesian proportional hazards model for prediction and variable selection, referred to as SVB. Our method, based on a mean-field variational approximation, overcomes the high computational cost of MCMC whilst retaining useful features, providing a posterior distribution for the parameters and offering a natural mechanism for variable selection via posterior inclusion probabilities. The performance of our proposed method is assessed via extensive simulations and compared against other state-of-the-art Bayesian variable selection methods, demonstrating comparable or better performance. Finally, we demonstrate how the proposed method can be used for variable selection on two transcriptomic datasets with censored survival outcomes, and how the uncertainty quantification offered by our method can be used to provide an interpretable assessment of patient risk.Availability and implementation:our method has been implemented as a freely available R package survival.svb (https://github.com/mkomod/survival.svb).
Nissen SE, Wolski K, Balog C, et al., 2022, Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels, JAMA: Journal of the American Medical Association, Vol: 327, Pages: 1679-1687, ISSN: 0098-7484
Importance Lipoprotein(a) (Lp[a]) is an important risk factor for atherothrombotic cardiovascular disease and aortic stenosis, for which there are no treatments approved by regulatory authorities.Objectives To assess adverse events and tolerability of a short interfering RNA (siRNA) designed to reduce hepatic production of apolipoprotein(a) and to assess associated changes in plasma concentrations of Lp(a) at different doses.Design, Setting, and Participants A single ascending dose study of SLN360, an siRNA targeting apolipoprotein(a) synthesis conducted at 5 clinical research unit sites located in the US, United Kingdom, and Australia. The study enrolled adults with Lp(a) plasma concentrations of 150 nmol/L or greater at screening and no known clinically overt cardiovascular disease. Participants were enrolled between November 18, 2020, and July 21, 2021, with last follow-up on December 29, 2021.Interventions Participants were randomized to receive placebo (n = 8) or single doses of SLN360 at 30 mg (n = 6), 100 mg (n = 6), 300 mg (n = 6), or 600 mg (n = 6), administered subcutaneously.Main Outcomes and Measures The primary outcome was evaluation of safety and tolerability. Secondary outcomes included change in plasma concentrations of Lp(a) to a maximum follow-up of 150 days.Results Among 32 participants who were randomized and received the study intervention (mean age, 50 [SD, 13.5] years; 17 women [53%]), 32 (100%) completed the trial. One participant experienced 2 serious adverse event episodes: admission to the hospital for headache following SARS-CoV-2 vaccination and later for complications of cholecystitis, both of which were judged to be unrelated to study drug. Median baseline Lp(a) concentrations were as follows: placebo, 238 (IQR, 203-308) nmol/L; 30-mg SLN360, 171 (IQR, 142-219) nmol/L; 100-mg SLN360, 217 (IQR, 202-274) nmol/L; 300-mg SLN360, 285 (IQR, 195-338) nmol/L; and 600-m
Leiter LA, Banach M, Catapano AL, et al., 2022, Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials, DIABETES OBESITY & METABOLISM, Vol: 24, Pages: 868-880, ISSN: 1462-8902
- Author Web Link
- Cite
- Citations: 24
Siostrzonek P, Brath H, Zweiker R, et al., 2022, Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? Results from the DA VINCI study, WIENER KLINISCHE WOCHENSCHRIFT, Vol: 134, Pages: 294-301, ISSN: 0043-5325
- Author Web Link
- Cite
- Citations: 5
Laufs U, Ballantyne CM, Banach M, et al., 2022, Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials, JOURNAL OF CLINICAL LIPIDOLOGY, Vol: 16, Pages: 286-297, ISSN: 1933-2874
- Author Web Link
- Cite
- Citations: 15
Gunn LH, Mckay A, Ray K, 2022, IS SAFEHEART 'SAFE' TO EXTEND TO OTHER POPULATIONS?: ASSESSMENT OF SAFEHEART RISK PREDICTION MODEL EXTERNAL VALIDITY AMONG AN ENGLISH COHORT OF ROUTINE FAMILIAL HYPERCHOLESTEROLAEMIA PARTICIPANTS, Publisher: ELSEVIER SCIENCE INC, Pages: 1634-1634, ISSN: 0735-1097
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.